Truffle Capital appointed Vincent Gardès to its biomed team as a senior partner, joining Dr. Philippe Pouletty, Alain Chevallier and Antoine Pau.
Mr. Gardès, former CEO of VEXIM, will generate new investments in the field of medical devices for Truffle Capital’s new BioMedTech fund and actively support Truffle’s portfolio companies. Since March 2018, Mr. Gardès also has been chairman of Affluent Medical, a Truffle Capital company.
Truffle is an independent venture capital firm focused on creating and financing start-ups with disruptive technologies in life sciences and information technology. It has created and financed three companies with its new BioMedTech Fund over the past few months, including HoliStick Medical, ArteDrone and Nonosive. In total, Truffle Capital could finance a dozen BioMedTech companies with its new fund and other co-investment funds.
VEXIM was founded by Truffle and acquired by Stryker in April 2018. “Having recently left VEXIM, I am now delighted to be on the other side of the fence and start building, with our BioMedTech Fund and other Truffle funds, new companies dedicated to revolutionizing interventional mini-invasive medicine,” Mr. Gardès said in a statement.
